Raloxifene Prevents Cardiac Hypertrophy and Dysfunction in Pressure-Overloaded Mice
- 1 February 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 43 (2) , 237-242
Abstract
17β-Estradiol reduces myocardial hypertrophy and left ventricular mass, suggesting that the selective estrogen receptor modulator raloxifene may have similar effects. However, it is not clear whether raloxifene inhibits both cardiac hypertrophy and dysfunction. We used transverse aortic-banded mice to produce pressure-overload cardiac hypertrophy and used neonatal rat ventricular cardiomyocytes to investigate the cellular mechanisms of raloxifene on cardiac hypertrophy. Left ventricular mass and fractional shortening of mice hearts were measured by transthoracic echocardiography. Protein synthesis of cardiomyocytes was evaluated by incorporation of [ 3 H]leucine into cardiomyocytes exposed to angiotensin II. Phosphorylation of mitogen-activated protein (MAP) kinase was also observed in cardiomyocytes. Raloxifene prevented increases in left ventricular mass and decreases of fractional shortening at 4 weeks after aortic banding. Pretreatment with raloxifene before angiotensin II stimulation inhibited the increase in [ 3 H]leucine incorporation into neonatal rat cardiomyocytes in a concentration-dependent manner. This inhibition was partially but not significantly attenuated by N G -nitro- l -arginine methyl ester ( l -NAME), an inhibitor of nitric oxide synthase, and completely abolished by ICI182780, an estrogen receptor antagonist. Although the phosphorylation of p38 MAP kinase, c-Jun N-terminal kinase (JNK), or extracellular signal-regulated protein kinase (ERK) in cardiomyocytes was significantly increased by angiotensin II stimulation as compared with the control, pretreatment with raloxifene attenuated p38 MAP kinase phosphorylation, but neither JNK nor ERK phosphorylation. We conclude that raloxifene inhibits cardiac hypertrophy and dysfunction and that the inhibition of p38 MAP kinase phosphorylation after the stimulation of estrogen receptors may be involved in the cellular mechanisms of this agent.Keywords
This publication has 25 references indexed in Scilit:
- CYP450- and COMT-Derived Estradiol Metabolites Inhibit Activity of Human Coronary Artery SMCsHypertension, 2003
- The Key Role of Caveolin-1 in Estrogen-Mediated Regulation of Endothelial Nitric Oxide Synthase Function in Cerebral Arterioles In vivoJournal of Cerebral Blood Flow & Metabolism, 2001
- Prognostic implications of left ventricular hypertrophyAmerican Heart Journal, 2001
- Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial CellsJournal of Biological Chemistry, 2001
- Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE study)The American Journal of Cardiology, 2001
- Methoxyestradiols Mediate the Antimitogenic Effects of Estradiol on Vascular Smooth Muscle Cells via Estrogen Receptor-Independent MechanismsBiochemical and Biophysical Research Communications, 2000
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Disruption of muscle architecture and myocardial degeneration in mice lacking desmin.Journal of Cell Biology, 1996
- Trans-cellular Desmin-Lamin B Intermediate Filament Network in Cardiac MyocytesJournal of Molecular and Cellular Cardiology, 1993
- Estrogen Replacement Therapy: Indications and ComplicationsAnnals of Internal Medicine, 1983